EUVIMEDEUVIMED entdecken
Open Access

Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer

Shilpa Gupta iD, Tu My To iD, Ryon Graf iD, Edward E Kadel iD, Norelle Reilly, Husam Albarmawi iD

JCO Precision Oncology · 2024-03 · (8)

DOI: 10.1200/po.23.00562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-03. Verfasst von Shilpa Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, PTEN Phosphohydrolase. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE It is estimated that the PTEN tumor suppressor gene is functionally lost in 40%-50% of patients with metastatic castration-resistant prostate cancer (mCRPC). There is limited information on the prognostic significance of PTEN status identified with genomic testing. This real-world cohort study assessed PTEN as a genetic biomarker using data from US-based oncology practices. METHODS This retrospective real-world cohort study used a deidentified US-based metastatic prostate cancer clinicogenomic database linked to longitudinal clinical data derived from electronic health records. Patients were aged 18 years and older and diagnosed with mCRPC between January 1, 2018, and June 30, 2021. Comprehensive genomic profiling (CGP) of tumor specimens was performed using next-generation sequencing. First-line (1L) and second-line (2L) treatment patterns were assessed and stratified by PTEN status. Kaplan-Meier methods and a multivariable Cox model were used to compare the real-world overall survival by PTEN status among patients who received 1L novel hormone therapy or taxanes. RESULTS In patients with mCRPC who underwent CGP, PTEN loss of function (LOF) was associated with decreased survival compared with intact PTEN (hazard ratio, 1.61 [95% CI, 1.07 to 2.42]; P = .024). The results were not influenced by 1L treatment type. 1L treatment patterns were similar between intact PTEN and PTEN LOF subgroups, with abiraterone and enzalutamide being the two most common treatments in both groups. Patients with PTEN LOF were less likely to receive 2L treatments than patients with intact PTEN. CONCLUSION PTEN LOF, identified with genomic testing, was associated with decreased survival and negative prognoses in patients with mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPTEN PhosphohydrolaseHumansMaleCohort StudiesPrognosisRetrospective StudiesTreatment Outcome

Substanzen

PTEN PhosphohydrolasePTEN protein, human

Autor:innen und Institutionen

  • Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Genentech, Inc, South San Francisco, CA.
  • Foundation Medicine, Inc, Cambridge, MA.

ORCID-Profile: Shilpa Gupta, Tu My To, Ryon Graf, Edward E Kadel, Husam Albarmawi

Zitieren

APA

Gupta, S., To, T. M., Graf, R., Kadel, E. E., Reilly, N., & Albarmawi, H. (2024). Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.23.00562

Vancouver

Gupta S, To TM, Graf R, Kadel EE, Reilly N, Albarmawi H. Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.23.00562

BibTeX
@article{Gupta2024,
  author = {Gupta, Shilpa and To, Tu My and Graf, Ryon and Kadel, Edward E and Reilly, Norelle and Albarmawi, Husam},
  title = {Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer},
  journal = {JCO Precision Oncology},
  year = {2024},
  number = {8},
  doi = {10.1200/po.23.00562}
}
Kostenlos starten →